Selective inhibitors of the ileal bile acid transporter (IBAT), which mediates luminal uptake of bile acids in enterocytes, reduce serum BA levels and improve growth and pruritus in patients with cholestatic liver disease [14, 15]. This evidence concerns the gene SLC10A2 and Cholestatic liver disease.